Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis.
Level 4 - case-series / case-control
Systematic review and meta-analysis of observational case-control neuroimaging studies
PubMed 22834460 · doi:10.1111/j.1399-5618.2012.01033.x
What was done
A systematic review and meta-analysis of Medline-indexed literature (January 1980 to April 2010) was conducted to evaluate proton magnetic resonance spectroscopy (1H-MRS) findings in bipolar disorder (BD). The search included studies assessing glutamate plus glutamine (Glx), Glx/creatine (Cr) ratio, glutamate (Glu), or Glu/Cr ratio across any brain region in adult or pediatric BD patients compared with healthy control subjects.
What was found
BD patients showed significantly increased Glx levels compared with healthy controls when pooling all brain regions. This elevation persisted in subgroup analyses of medicated patients, non-medicated patients, and frontal brain regions in adults. Whole-brain Glx/Cr and Glu showed non-significant upward trends in patients compared to controls (p = 0.09). No significant difference was detected for the Glu/Cr ratio. The abstract does not provide exact effect sizes, confidence intervals, or sample counts.
Why it matters
These findings synthesize previously conflicting 1H-MRS neuroimaging studies to support the hypothesis that glutamatergic system alterations play a role in bipolar disorder pathophysiology.
Limits
The abstract does not disclose the total number of included studies, overall participant count, effect sizes, confidence intervals, or measures of between-study heterogeneity. The impact of specific mood states (e.g., euthymic, manic, depressed) and differences in MRS acquisition parameters across studies are not detailed.
Cited by
- supports Systematic reviews establish that elevated glutamate is a major feature of bipolar disorder and epilepsy, and glutamate reduction is a marker of treatment response.